The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Marcelo V. Negrao, MD, discusses updated efficacy and safety data for first-line olomorasib plus chemoimmunotherapy in KRAS G12C–mutant NSCLC.

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies.

Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.

Fadi Haddad, MD, discusses how to approach proper TKI adherence and selection in clinical practice for CML.

Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.

Shannon N. Westin, MD, MPH, FACOG, discusses interim overall survival data from the phase 3 DUO-E trial in advanced or recurrent endometrial cancer.

Two MD Anderson Cancer Center researchers were elected to the National Academy of Medicine for contributions to cancer care and research.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.

Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.

Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.

D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.

The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.

Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.

MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses first-line efficacy data for divarasib plus pembrolizumab in KRAS G12C+ NSCLC from the KRASCENDO-170 study.

ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.